Septerna (NASDAQ:SEPN) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Septerna (NASDAQ:SEPN) announced its quarterly earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14, FiscalAI reports. Septerna had a negative return on equity of 9.59% and a negative net margin of 24.51%.The firm had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million.

Septerna Price Performance

Shares of SEPN traded up $1.07 on Wednesday, reaching $48.83. The company’s stock had a trading volume of 433,093 shares, compared to its average volume of 350,980. The stock has a market capitalization of $2.20 billion, a P/E ratio of -92.01 and a beta of 2.29. The stock’s 50 day simple moving average is $34.94 and its two-hundred day simple moving average is $29.25. Septerna has a 12-month low of $10.74 and a 12-month high of $51.10.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SEPN. Guggenheim upped their target price on shares of Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright boosted their price objective on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a research report on Tuesday. Raymond James Financial restated a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a report on Tuesday. Finally, Truist Financial boosted their target price on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.22.

Insider Buying and Selling

In other news, insider Samira Shaikhly sold 2,178 shares of Septerna stock in a transaction on Monday, June 29th. The shares were sold at an average price of $35.18, for a total transaction of $76,622.04. Following the transaction, the insider owned 793 shares in the company, valued at $27,897.74. This trade represents a 73.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Daniel D. Long sold 3,334 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total transaction of $114,922.98. Following the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,323,321.64. The trade was a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 47,828 shares of company stock valued at $1,584,314. 5.80% of the stock is owned by corporate insiders.

Institutional Trading of Septerna

Several hedge funds have recently bought and sold shares of SEPN. Goldman Sachs Group Inc. grew its stake in shares of Septerna by 86.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the period. First Light Asset Management LLC purchased a new stake in Septerna in the 4th quarter worth approximately $17,308,000. Primecap Management Co. CA bought a new stake in Septerna during the 4th quarter worth approximately $15,225,000. Perceptive Advisors LLC bought a new stake in Septerna during the 2nd quarter worth approximately $5,723,000. Finally, VR Adviser LLC purchased a new position in Septerna during the second quarter valued at approximately $5,713,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.